REFERENCES

Abad, S., Vega, A., Rincon, D., Hernandez, E., et al., 2017. Effectiveness of direct-acting antivirals in Hepatitis C virus infection in hemodialysis patients. *Nefrologia* 37(2): 158-163.

Abozeid, M., Alsebaey, A., Abdelsameea, E., Othman, W., 2018. High efficacy of Generic and Brand Direct Acting Antivirals in Treatment of Chronic Hepatitis C. *International Journal of Infectious Diseases.*

Aki, M., Hindawi, Ali, et al. 2016. Fibrosis in Chronic Hepatitis C: Correlation between Immunohistochemically-Assessed Virus Load with Steatosis and Cellular Iron Content. *World Journal of Gastroenterology* 4(4):578-584.

Arends, J.E., Kracht, A.I.M., 2016. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. *Clinical Microbiology and Infection* 22(2016): 846-852.

Asselah, T., Marcellin, P., Schinazi, R. F., 2018. Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?. *Wiley Online Library* 38(1):7-13

Beld, M., Penning, M., Goudsmit, J., 1998. Different Hepatitis C Virus (HCV) RNA Load Profiles Following Seroconversion among Injecting Drug Users without Correlation with HCV Genotype and Serum Alanine Aminotransferase Levels. *Journal Clinical Microbiology* 36(4):872-877.

Blach, S., Zeuzem, S., Manns, M., 2017. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol* 2:161-76.

Brian-Marrugo, O.L., Ramos-Jimenez, J., Barrera-Saldana, H., Rojas-Martinez, A., et al., 2015. History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C. *Medicina Universitaria* 17(68): 165-174.

Derbala, M., Elbadri., M., et al., 2015. Aspartate transaminase to platelet ratio index in hepatitis C virus and *Schistosomiasis* coinfection. *World journal of gastroenterology* 21(46): 13132-13139.

Du, L., Tang, H., 2016. An insight into the molecular characteristics of hepatitis C virus for clinicians. *Saudi Med J* 37(5):483-491.

Feld, J., Jacobson, I.M., Sulkowski, M.S., et al., 2016. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. *Wiley Liver International* 37:5-18.

Fereira, V.L., Borba, H.H., Wiens, A., Pedroso, M.L., et al., 2018. Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil. *Infectious Disease* 22(3):186-192.

Fox, R., Spach, D., 2018. Diagnosis of Acute HCV infection. Hepatitis C online [Online][Cited January, 9th 2019]. Available from: URL: https://www.hepatitisc.uw.edu/go/screening-diagnosis/acute-diagnosis/core-concept/all.

Grando, A.V., Roberto, P., Pessoa, M.G., et al., 2017. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. *Journal of Med Trop São Paulo* 59(67);1-8.

Gani, R.A., et al., 2014. *Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia*. Perhimpunan Peneliti Hati, Indonesia.

Hepatitis C Treatment Information Project. (2018). *THE FOUR CLASSES OF HEP C TREATMENT DAAS*. [online] Available at: http://www.hepctip.ca/daas/ [Accessed 6 Oct. 2018].

Holtzman, D., 2017. Hepatitis C. Infectious Disease Related to Travel. [Online][Cited January, 7th 2019]. Available from: URL: https://wwwnc.cdc.gov/travel/ yellowbook/2018/infectious-diseases-related-to-travel/hepatitis-c

Kiser, J., Flexner, C., 2013. Direct-Acting Antiviral Agents for Hepatitis C Virus Infection. *Annu Rev Pharmaco Toxicol* 53:427-449

Marin, J., Allen J., et al. 2009. APRI as a predictor of early viral response in chronic hepatitis C patients. *World Journal of Gastroenterology* 15(39):4923-4927.

Modi, A.A., Liang, T.J., 2008. Hepatitis C: A clinical review. Oral dis [Online][Cited January, 8th 2019];14(1). Available from: URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803488

Munir, S., Saleem, S., 2010. Hepatitis C Treatment: current and future perspectives. *Virology Journal* 7:296.

Murphy, D.G., Sablon, E., Chamberland, J., 2014.Hepatitis C Virus Genotype 7, a New Genotype Originating from Central Africa. *Journal of Clinical Microbiology* 53:967-972.

Pawlotsky, J.M., 2004. Pathophysiology of hepatitis C virus infection and related liver disease. *Trends in Microbiology* 12(2):96-102.

Pearl, R.B., Taub, N., 2011. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. *Clinical Infectious Disease* 52(7):889-900.

Petruzzielo, A., Marigliano, S., Loquercio, G., 2016. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. *World Journal of Gastroenterology* 22(34):7824-7840.

Rong, L., Perelson, A.S., 2010. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. *NIH Public Access* 30(2):131-148.

Rosenthal, E., Graham, C., 2016. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. *BioMed Central* 11:24

Saeed, S., Strumpf, E.C., Moodie, E., Young, J., Nitulescu, R., et al., 2017. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. *Journal of the International AIDS Society* 20(3).

Scott, J.D., Kim, H.N., 2018. Goals and Benefit with HCV Treatment. Hepatitis C Online [Online][Cited February, 13th 2019]. Available from: URL: https://www.hepatitisc.uw.edu/go/evaluation-treatment/treatment-goals-predicting-response/core-concept/all

Shaffer, M., Ahuja, D., 2017. Hepatitis C: Screening changes, treatment advances. *The Journal of Family Practice* 66(3): 136-140,142-144.

Sulaiman, A.S., Gani, R.A., Hasan, I., et al., 2018. Efficacy of Combination Sofosbuvir, Pegylated Interferon, and Ribavirin for Treatment of Hepatitis C Virus Genotype 1 Infection in Indonesia. *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy* 19(2):74-78

Westbrook, R., Dusheiko, G., 2014. Natural History of Hepatitis C. *Journal of Hepatology* 61:58-68

Woolston, S.L., Kim, H.N., 2018. Cost and Access to Direct-Acting Antiviral Agents. Hepatitis C Online [Online][Cited January, 7th 2019]. Available from: URL: https://www.hepatitisc.uw.edu/go/evaluation-treatment/cost-access-medications/core-concept/all

World Health Organization, 2017. Hepatitis C [Online][Cited January, 7th 2019]. Available from: URL: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

Xu, X.W., Wu, X., Chen, K., et al., 2018. Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China An observational study. *Medicine* 97:38.